+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cardiac Biomarkers Testing Market, by Type, by Application, by Testing Location, and by Region, Market Outlook 2027

  • PDF Icon

    Report

  • 100 Pages
  • June 2020
  • Region: Global
  • Rockville Research
  • ID: 5119026

Industry Insights


According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2027, growing at a CAGR of 8.5% in the period 2020 to 2027. Growth of the market is driven by the prevalence of cardiovascular cases, increasing geriatric population, higher precision and its non-invasiveness.

Cardiac biomarkers testing is used for diagnosis of various cardiovascular diseases such as cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome. Cardiac Biomarkers are basically protein molecules that are released into the bloodstream after heart damage or heart-stress. Hence measuring biomarkers usually serves as an important early step in diagnosing a heart attack.

The use of cardiac biomarkers in combination are widely applied in clinical diagnosis, risk stratification, and management of patients with or without cardiovascular diseases. One of the potent cardiac biomarker combinations is that of cTn and BNP which is quantitative markers of cardiac damage.

Report Scope


This report “Global Cardiac Biomarkers Testing Market [By Type - Creatine Kinase (CK-MB), Myoglobins, Ischemia Modified Albumin (IMA), Troponins & Natriuretic Peptides; By Application - Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure & Atherescelerosis; By Testing Location – POC Testing & Laboratory Testing; By Region- North America (The US), Europe (The UK & Germany) & Asia Pacific (China & Japan)] Market Outlook 2027” provides detailed analysis of the global cardiac biomarkers testing market from qualitative and quantitative outlooks during the forecast period across various regional markets. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Parameter Description


  • Base year: 2016
  • Forecast period: 2020 – 2027
  • Market sizing: Revenue in US$ Billions & CAGR for the period 2016 to 2027
  • Country coverage: The US, The UK, Germany, Japan & China
  • Vendor scope: Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories & BioMerieux
  • Report coverage: Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles

Segments Covered


The report provides revenue forecasts for global, regional, and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the publisher has segmented global cardiac biomarkers testing market report on the basis of type, applications, testing location and geography.

Biomarkers Testing Type Outlook, Revenue (2018 – 2027E, US$ Billions)


  • Creatine Kinase (CK-MB)
  • Myoglobins
  • Ischemia Modified Albumin (IMA)
  • Troponins
  • Natriuretic Peptides

Biomarkers Testing Application Outlook, Revenue (2018 – 2027E, US$ Billions)


  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Atherescelerosis

Biomarkers Testing Location Outlook, Revenue (2018 – 2027E, US$ Billions)


  • POC Testing
  • Laboratory Testing

Regional Outlook, Revenue (2018 – 2027E, US$ Billions)


  • North America
  • Europe
  • Asia Pacific

Country Outlook, Revenue (2018 – 2027E, US$ Billions)


  • The US
  • The UK
  • Germany
  • Japan
  • China

Vendors Outlook, Revenue (2015 – 2019, US$ Billions)


  • Roche Diagnostics
  • Abbott Laboratories
  • Siemens Healthcare
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories
  • BioMerieux

Target Audience


  • Drug Manufacturers
  • Chemical Suppliers
  • End Users
  • Research Professionals
  • Healthcare Consultancies
  • Regulatory Bodies

Key Questions Answered in the Report


  • The historical market size of the cardiac biomarkers testing market in value terms in the period 2016 to 2019 in US$ Billions.
  • Projected market growth in the forecasted period 2020 to 2027 with estimated revenue for each year in US$ Billions.
  • Regional and country analysis of the cardiac biomarkers testing market is provided for the period 2018 to 2027.
  • Market drivers, restraints and industry trends that has an impact on revenue.
  • Profiling of major companies with a detailed analysis of their cardiac biomarkers testing products.

Table of Contents


1. Executive Summary2. Research Methodology
3. Cardiovascular Diseases
3.1 Overview
3.2 Diagnosis


4. Cardiac Biomarkers Testing
4.1 Cardiac Biomarkers
4.2 Classification
4.2.1 Creatine Kinase (CK-MB)
4.2.2 Troponins T & I
4.2.3 Myoglobin
4.2.4 B-type natriuretic peptide (BNPs)
4.2.5 Ischemia-Modified Albumin (IMA)


5. Market Analysis
5.1 Market Sizing (Actual & Forecasted)
5.2 Market Share Analysis
5.2.1 Market Share by Type
5.2.2 Market Share by Application
5.2.3 Market Share by Product
5.2.4 Market Share by Testing Location
5.2.6 Market Share by Region


6. Market Segmentation
6.1 By Type
6.1.1 Creatine Kinase (CK-MB)
6.1.1.1 Overview
6.1.1.2 Market Sizing (Actual & Forecasted)
6.1.2 Myoglobins
6.1.2.1 Overview
6.1.2.2 Market Sizing (Actual & Forecasted)
6.1.3 Ischemia Modified Albumin (IMA)
6.1.3.1 Overview
6.1.3.2 Market Sizing (Actual & Forecasted)
6.1.4 Troponins
6.1.4.1 Overview
6.1.4.2 Market Sizing (Actual & Forecasted)
6.1.5 Natriuretic Peptides
6.1.5.1 Overview
6.1.5.2 Market Sizing (Actual & Forecasted)
6.2 By Application
6.2.1 Acute Coronary Syndrome
6.2.1.1 Overview
6.2.1.2 Market Sizing (Actual & Forecasted)
6.2.2 Myocardial Infarction
6.2.2.1 Overview
6.2.2.2 Market Sizing (Actual & Forecasted)
6.2.3 Congestive Heart Failure
6.2.3.1 Overview
6.2.3.2 Market Sizing (Actual & Forecasted)
6.2.4 Atherescelerosis
6.2.4.1 Overview
6.2.4.2 Market Sizing (Actual & Forecasted)
6.3 By Testing Location
6.3.1 POC Testing
6.3.1.1 Overview
6.3.1.2 Market Sizing (Actual & Forecasted)
6.3.2 Laboratory Testing
6.3.2.1 Overview
6.3.2.2 Market Sizing (Actual & Forecasted)


7. Regional Analysis
7.1 North America
7.1.1 Market Sizing (Actual & Forecasted)
7.1.2 The US
7.1.2.1 Market Sizing (Actual & Forecasted)
7.2 Asia Pacific
7.2.1 Market Sizing (Actual & Forecasted)
7.2.2 China
7.2.2.1 Market Sizing (Actual & Forecasted)
7.2.3 Japan
7.2.3.1 Market Sizing (Actual & Forecasted)
7.3 Europe
7.3.1 Market Sizing (Actual & Forecasted)
7.3.2 Germany
7.3.2.1 Market Sizing (Actual & Forecasted)
7.3.3 The UK
7.3.3.1 Market Sizing (Actual & Forecasted)


8. Market Dynamics
8.1 Industry Trends & Development
8.1.1 Use of Cardiac Biomarkers in Combination
8.1.2 Development of Innovative Products
8.1.3 Rapid POC Diagnostic Testing
8.2 Growth Drivers
8.2.1 Prevalence of Cardiovascular Diseases
8.2.2 Increasing Geriatric Population
8.2.3 Higher Precision
8.2.4 Non-Invasive in Nature
8.3 Challenges
8.3.1 Stringent Regulatory Compliance
8.3.2 High Cost of Treatment
8.3.3 Limited Specificity


9. Competitive Landscape
9.1 Financial Analysis


10. Company Profiles
10.1 Roche Diagnostics
10.2 Abbott Laboratories
10.3 Siemens Healthcare
10.4 Becton, Dickinson and Company
10.5 Bio-Rad Laboratories
10.6 BioMerieux


List of Tables and Figures
Figure 1: Research Methodology
Figure 2: Types of Cardiovascular Diseases
Figure 3: History of Cardiac Biomarkers Testing
Table 1: Cardiac Biomarkers Analysis
Figure 4: Classification of Cardiac Biomarkers
Table 2: Advantages & Disadvantages of Various Cardiac Biomarkers
Figure 5: Global Cardiac Biomarkers Testing Market Size by Value, 2016-27E (US$ Billions)
Figure 6: Global Cardiac Biomarker Testing Market Share by Type (2019)
Figure 7: Global Cardiac Biomarker Testing Market Share by Application (2019)
Figure 8: Global Cardiac Biomarker Testing Market Share by Product (2019)
Figure 9: Global Cardiac Biomarker Testing Market Share by Testing Location (2019)
Figure 10: Global Cardiac Biomarker Testing Market Share by Region (2019)
Table 3: Cardiac Biomarker - Creatine Kinase (CK-MB) Analysis
Figure 11: Global Cardiac Biomarkers Testing Market by Type - Creatine Kinase (CK-MB) Market Size by Value, 2018-27E (US$ Billions)
Table 4: Cardiac Biomarker - Myoglobins Analysis
Figure 12: Global Cardiac Biomarkers Testing Market by Type – Myoglobins Market Size by Value, 2018-27E (US$ Billions)
Table 5: Cardiac Biomarker - Ischemia Modified Albumin (IMA) Analysis
Figure 13: Global Cardiac Biomarkers Testing Market by Type - Ischemia Modified Albumin (IMA) Market Size by Value, 2018-27E (US$ Billions)
Table 5: Cardiac Biomarker - Troponin Analysis
Figure 14: Cardiac Troponins & Cardiomyocyte Damage
Figure 15: Global Cardiac Biomarkers Testing Market by Type - Troponins Market Size by Value, 2018-27E (US$ Billions)
Table 6: Cardiac Biomarker – Natriuretic Peptides Analysis
Figure 16: Release of BNP and NT-proBNP
Table 7: Comparison of Properties of B-type Natriuretic Peptides
Figure 17: Global Cardiac Biomarkers Testing Market by Type - Natriuretic Peptides Market Size by Value, 2018-27E (US$ Billions)
Figure 18: Diagrammatic Representation of Acute Coronary Syndrome
Figure 19: Global Cardiac Biomarkers Testing Market by Application – Acute Coronary Syndrome Market Size by Value, 2018-27E (US$ Billions)
Figure 20: Diagrammatic Representation of Myocardial Infarction
Figure 21: Global Cardiac Biomarkers Testing Market by Application – Myocardial Infarction Market Size by Value, 2018-27E (US$ Billions)
Figure 22: Diagrammatic Representation of Congestive Heart Failure
Figure 23: Global Cardiac Biomarkers Testing Market by Application – Congestive Heart Failure Market Size by Value, 2018-27E (US$ Billions)
Figure 24: Diagrammatic Representation of Atherescelerosis
Figure 25: Global Cardiac Biomarkers Testing Market by Application – Atherescelerosis Market Size by Value, 2018-27E (US$ Billions)
Table 8: Cardiac Biomarkers POC Testing – Advantages & Disadvantages
Figure 26: Global Cardiac Biomarkers Testing Location – POC Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 27: Global Cardiac Biomarkers Testing Location – Laboratory Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 28: North America Cardiac Biomarkers Testing Market Size by Value, 2016-27E (US$ Billions)
Figure 29: The US Cardiac Biomarkers Testing Market Size by Value, 2016-27E (US$ Billions)
Figure 30: Asia Pacific Cardiac Biomarkers Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 31: China Cardiac Biomarkers Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 32: Japan Cardiac Biomarkers Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 33: Europe Cardiac Biomarkers Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 34: Germany Cardiac Biomarkers Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 35: The UK Cardiac Biomarkers Testing Market Size by Value, 2018-27E (US$ Billions)
Figure 36: Global Cardiovascular Disease Incidences, 2012-19 (Millions)
Figure 37: Percentage of Death by Cardiovascular Disease in the US (2019)
Figure 38: Global Ageing (Aged Above 65 Years) Population, 2012-19 (Millions)
Table 9: Global Cardiac Biomarkers Testing Market Players Financial Analysis (2019)
Table 10: Global Cardiac Biomarkers Testing Market Players Revenue Analysis, FY2016-FY2019 (US$ Billions)
Figure 39: Roche Diagnostics Revenue by Business Segment (FY2019)
Table 11: Roche Diagnostics Cardiac Biomarkers Clinical Pipeline
Figure 40: Roche Diagnostics Net Sales, FY2015-FY2019 (US$ Billions)
Figure 41: Abbott Laboratories Revenue by Business Segment (FY2019)
Table 12: Abbott Laboratories Cardiac Biomarkers Clinical Pipeline
Figure 42: Abbott Laboratories Net Sales, FY2015-FY2019 (US$ Billions)
Figure 43: Siemens Healthcare Revenue by Business Segment (FY2019)
Table 13: Siemens Healthcare Cardiac Biomarkers Clinical Pipeline
Figure 44: Siemens Healthcare Net Sales, FY2015-FY2019 (US$ Billions)
Figure 45: Becton, Dickinson and Company Revenue by Business Segment (FY2019)
Table 14: Becton, Dickinson and Company Cardiac Biomarkers Clinical Pipeline
Figure 46: Becton, Dickinson and Company Net Sales, FY2015-FY2019 (US$ Billions)
Figure 47: Bio-Rad Laboratories Revenue by Business Segment (FY2019)
Table 15: Bio-Rad Laboratories Cardiac Biomarkers Clinical Pipeline
Figure 48: Bio-Rad Laboratories Net Sales, FY2015-FY2019 (US$ Billions)
Figure 49: BioMerieux Revenue by Business Segment (FY2019)
Table 16: BioMerieux Cardiac Biomarkers Clinical Pipeline
Figure 50: BioMerieux Net Sales, FY2015-FY2019 (US$ Billions)

Executive Summary

Cardiac Biomarkers are the protein molecules that are released into the bloodstream after heart damage or heart-stress. It serves as a tool for the detection of various cardiovascular diseases (CVD) such as cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS). The common cardiac biomarkers that are tested for CVD include troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and many more. Creatine kinase was the first cardiac protein that has been widely used by doctors for the diagnosis of heart attacks. Recently, troponin has emerged as the more important blood protein for detecting heart cell damages.


There are a number of factors that impact the growth of the cardiac biomarkers market. Growth of the market is primarily attributed to the prevalence of cardiovascular cases, increasing geriatric population, higher precision and its non-invasiveness. With the rise in the number of cardiovascular disorders, there is a subsequent upsurge in demand for diagnostic and testing of various cardiovascular diseases, development and advancement in cardiac biomarkers. However, the market faces various challenges due to stringent regulatory compliance in the industry, high cost of treatment, and limited specificity associated with the use of individual cardiac markers for testing.


The report “Global Cardiac Biomarkers Testing Market [By Type - Creatine Kinase (CK-MB), Myoglobins, Ischemia Modified Albumin (IMA), Troponins & Natriuretic Peptides; By Application - Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure & Atherescelerosis; By Testing Location - POC Testing & Laboratory Testing; By Region- North America (The US), Europe (The UK & Germany) & Asia Pacific (China & Japan)] Market Outlook 2027” provides an in-depth analysis of the current scenario, detailed market outlook of the global cardiac biomarkers testing market. Future forecasts of the market overall and across various regional markets have been provided in the report until 2027. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.


Major industry players operating in the global cardiac biomarker testing market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories & BioMerieux, among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global cardiac biomarker testing market.


Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • BioMerieux
  • Roche Diagnostics
  • Siemens Healthcare

Methodology

Loading
LOADING...